Gerresheimer (OTCMKTS:GRRMF – Get Free Report) and Singular Genomics Systems (NASDAQ:OMIC – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Analyst Recommendations
This is a summary of current recommendations and price targets for Gerresheimer and Singular Genomics Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gerresheimer | 0 | 0 | 4 | 0 | 3.00 |
| Singular Genomics Systems | 0 | 2 | 0 | 0 | 2.00 |
Gerresheimer currently has a consensus price target of $98.50, indicating a potential downside of 13.86%. Singular Genomics Systems has a consensus price target of $2.75, indicating a potential upside of 374.22%. Given Singular Genomics Systems’ higher probable upside, analysts clearly believe Singular Genomics Systems is more favorable than Gerresheimer.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gerresheimer | N/A | N/A | N/A | $2.27 | 50.37 |
| Singular Genomics Systems | $760,000.00 | 54.97 | -$90.88 million | ($1.30) | -0.45 |
Gerresheimer has higher earnings, but lower revenue than Singular Genomics Systems. Singular Genomics Systems is trading at a lower price-to-earnings ratio than Gerresheimer, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Gerresheimer and Singular Genomics Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gerresheimer | N/A | N/A | N/A |
| Singular Genomics Systems | N/A | -37.79% | -29.81% |
Insider & Institutional Ownership
53.2% of Gerresheimer shares are held by institutional investors. Comparatively, 49.8% of Singular Genomics Systems shares are held by institutional investors. 21.9% of Singular Genomics Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Gerresheimer beats Singular Genomics Systems on 7 of the 10 factors compared between the two stocks.
About Gerresheimer
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment platforms. It also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, the company offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. It offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, diagnostics, medical technology, cosmetics, and food and beverage industries. The company was founded in 1864 and is based in Düsseldorf, Germany.
About Singular Genomics Systems
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.
